{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:43:35Z","timestamp":1792028615780,"version":"4.4.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404719"],"award-info":[{"award-number":["82404719"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010226","name":"Department of Education of Guangdong Province","doi-asserted-by":"publisher","award":["2024KSYS006"],"award-info":[{"award-number":["2024KSYS006"]}],"id":[{"id":"10.13039\/501100010226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014544","name":"Institute for Health Metrics and Evaluation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010722","name":"Harbin Medical University","doi-asserted-by":"publisher","award":["HDHY2025002"],"award-info":[{"award-number":["HDHY2025002"]}],"id":[{"id":"10.13039\/100010722","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004024","name":"Jinan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.metabol.2026.156549","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:14:54Z","timestamp":1770164094000},"page":"156549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Rising burden of MASLD and CKM syndrome in Asia: A decade of trends and future projections"],"prefix":"10.1016","volume":"178","author":[{"given":"Tianqi","family":"Duo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baofeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.metabol.2026.156549_bb0005","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2026.156549_bb0010","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCULATIONAHA.124.070535","article-title":"Cardiovascular-liver-metabolic health: recommendations in screening, diagnosis, and management of metabolic dysfunction-associated steatotic liver disease in cardiovascular disease via modified Delphi approach","volume":"151","author":"Chew","year":"2025","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.metabol.2026.156549_bb0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.metabol.2026.156549_bb0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.metabol.2026.156549_bb0025","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults","volume":"11","author":"Huang","year":"2025","journal-title":"Nat Rev Dis Primers"},{"issue":"20","key":"10.1016\/j.metabol.2026.156549_bb0030","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.metabol.2026.156549_bb0035","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.metabol.2026.156549_bb0040","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.041834","article-title":"Population-Based Study on the Coexistence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Chronic Kidney Disease","volume":"14","author":"Goh","year":"2025","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"10.1016\/j.metabol.2026.156549_bb0045","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1038\/s41591-024-03223-z","article-title":"Integrating liver endpoints in clinical trials of cardiovascular and kidney disease","volume":"30","author":"Zannad","year":"2024","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.metabol.2026.156549_bb0050","article-title":"Comprehensive review of cardiovascular disease risk in nonalcoholic fatty liver disease","volume":"9","author":"Josloff","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"issue":"11","key":"10.1016\/j.metabol.2026.156549_bb0055","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"72","author":"En Li Cho","year":"2023","journal-title":"Gut"},{"issue":"Suppl1","key":"10.1016\/j.metabol.2026.156549_bb0060","first-page":"S1","article-title":"Type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"10","author":"Amiri Dash Atan","year":"2017","journal-title":"Gastroenterol Hepatol Bed Bench"},{"issue":"2","key":"10.1016\/j.metabol.2026.156549_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.102344","article-title":"Cardiovascular-Kidney-Metabolic (CKM) syndrome: a state-of-the-art review","volume":"49","author":"Sebastian","year":"2024","journal-title":"Curr Probl Cardiol"},{"issue":"2","key":"10.1016\/j.metabol.2026.156549_bb0070","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3390\/biom15020213","article-title":"From cardiovascular-kidney-metabolic syndrome to cardiovascular-renal-hepatic-metabolic syndrome: proposing an expanded framework","volume":"15","author":"Theodorakis","year":"2025","journal-title":"Biomolecules"},{"issue":"11","key":"10.1016\/j.metabol.2026.156549_bb0075","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.45309","article-title":"Prevalence of cardiovascular-kidney-metabolic syndrome stages by social determinants of health","volume":"7","author":"Zhu","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"21","key":"10.1016\/j.metabol.2026.156549_bb0080","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1001\/jama.2024.6892","article-title":"Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020","volume":"331","author":"Aggarwal","year":"2024","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.metabol.2026.156549_bb0085","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/hep.32228","article-title":"Global burden of NAFLD and chronic liver disease among adolescents and young adults","volume":"75","author":"Paik","year":"2022","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.metabol.2026.156549_bb0090","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"(EASO). EAftSotLEEAftSoDEEAftSoO","year":"2024","journal-title":"J Hepatol"},{"issue":"10440","key":"10.1016\/j.metabol.2026.156549_bb0095","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"Ferrari","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156549_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155958","article-title":"Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019","volume":"158","author":"Danpanichkul","year":"2024","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.metabol.2026.156549_bb0105","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/s41591-022-01990-1","article-title":"The global burden of disease study at 30 years","volume":"28","author":"Murray","year":"2022","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.metabol.2026.156549_bb0110","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2026.156549_bb0115","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pcad.2024.10.012","article-title":"Cardiovascular-kidney-metabolic syndrome\u2013an integrative review","volume":"87","author":"Lopes","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.metabol.2026.156549_bb0120","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.metabol.2026.156549_bb0125","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"10.1016\/j.metabol.2026.156549_bb0130","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.3350\/cmh.2022.0367","article-title":"MAFLD: how is it different from NAFLD?","volume":"29","author":"Gofton","year":"2022","journal-title":"Clin Mol Hepatol"},{"issue":"21","key":"10.1016\/j.metabol.2026.156549_bb0135","doi-asserted-by":"crossref","first-page":"e2141","DOI":"10.1212\/WNL.0000000000207218","article-title":"Burden of common neurologic diseases in Asian countries, 1990\u20132019: an analysis for the Global Burden of Disease Study 2019","volume":"100","author":"Wang","year":"2023","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.metabol.2026.156549_bb0140","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euae195","article-title":"Global burden of atrial fibrillation\/atrial flutter and its attributable risk factors from 1990 to 2021","volume":"26","author":"Cheng","year":"2024","journal-title":"Europace"},{"issue":"2","key":"10.1016\/j.metabol.2026.156549_bb0145","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/ckj\/sfac218","article-title":"Temporal trends in prevalence and mortality for chronic kidney disease in China from 1990 to 2019: an analysis of the Global Burden of Disease Study 2019","volume":"16","author":"Li","year":"2023","journal-title":"Clin Kidney J"},{"issue":"2","key":"10.1016\/j.metabol.2026.156549_bb0150","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.metabol.2026.156549_bb0155","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MCG.0000000000001172","article-title":"Among Medicare patients with hepatocellular carcinoma, non\u2013alcoholic fatty liver disease is the most common etiology and cause of mortality","volume":"54","author":"Hester","year":"2020","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"10.1016\/j.metabol.2026.156549_bb0160","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/hep.30161","article-title":"Changing trends in etiology-based and ethnicity-based annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States","volume":"69","author":"Kim","year":"2019","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.metabol.2026.156549_bb0165","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/ajg.2017.175","article-title":"Trends in 30-day and 1-year mortality among patients hospitalized with cirrhosis from 2004 to 2013","volume":"112","author":"Kanwal","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.metabol.2026.156549_bb0170","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41575-018-0055-0","article-title":"The changing epidemiology of liver diseases in the Asia\u2013Pacific region","volume":"16","author":"Wong","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.metabol.2026.156549_bb0175","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3350\/cmh.2024.0109","article-title":"Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"30","author":"Crane","year":"2024","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.metabol.2026.156549_bb0180","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11886-024-02025-6","article-title":"The global epidemic of metabolic fatty liver disease","volume":"26","author":"Lee","year":"2024","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.metabol.2026.156549_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154770","article-title":"Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk","volume":"119","author":"Muzurovi\u0107","year":"2021","journal-title":"Metabolism"},{"issue":"20","key":"10.1016\/j.metabol.2026.156549_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242015473","article-title":"Metabolic-dysfunction-associated steatotic liver disease-its pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments","volume":"24","author":"Yanai","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.metabol.2026.156549_bb0195","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","article-title":"Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review","volume":"23","author":"Zheng","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.metabol.2026.156549_bb0200","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/gutjnl-2023-331003","article-title":"Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease","volume":"73","author":"Lee","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.metabol.2026.156549_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154433","article-title":"MAFLD and risk of CKD","volume":"115","author":"Sun","year":"2021","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.metabol.2026.156549_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101506","article-title":"Steatotic liver disease, MASLD and risk of chronic kidney disease","volume":"50","author":"Bilson","year":"2024","journal-title":"Diabetes Metab"},{"issue":"4","key":"10.1016\/j.metabol.2026.156549_bb0215","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41581-021-00519-y","article-title":"Association of metabolic dysfunction-associated fatty liver disease with kidney disease","volume":"18","author":"Wang","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"Suppl. 2","key":"10.1016\/j.metabol.2026.156549_bb0220","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s12072-024-10660-y","article-title":"MAFLD as part of systemic metabolic dysregulation","volume":"18","author":"Zhao","year":"2024","journal-title":"Hepatol Int"},{"issue":"5","key":"10.1016\/j.metabol.2026.156549_bb0225","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s12072-023-10558-1","article-title":"A simpler definition of MAFLD precisely predicts incident metabolic diseases: a 7-year cohort study","volume":"17","author":"Xie","year":"2023","journal-title":"Hepatol Int"},{"key":"10.1016\/j.metabol.2026.156549_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155919","article-title":"Obesity and dyslipidemia in early life: impact on cardiometabolic risk","volume":"156","author":"Zeljkovic","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156549_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155642","article-title":"Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States","volume":"146","author":"Golabi","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156549_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155997","article-title":"Management of patients with the cardio renal liver metabolic syndrome: the need for a multidisciplinary approach in research, education and practice","volume":"159","author":"Angelidi","year":"2024","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.metabol.2026.156549_bb0245","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00125-020-05132-5","article-title":"Why are South Asians prone to type 2 diabetes? A hypothesis based on underexplored pathways","volume":"63","author":"Narayan","year":"2020","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.metabol.2026.156549_bb0250","doi-asserted-by":"crossref","first-page":"552","DOI":"10.4239\/wjd.v15.i3.552","article-title":"KCNQ1 rs2237895 gene polymorphism increases susceptibility to type 2 diabetes mellitus in Asian populations","volume":"15","author":"Li","year":"2024","journal-title":"World J Diabetes"},{"issue":"7","key":"10.1016\/j.metabol.2026.156549_bb0255","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41575-025-01058-8","article-title":"Metabolic diseases in the East Asian populations","volume":"22","author":"Sun","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2026.156549_bb0260","article-title":"The ALDH2 gene rs671 polymorphism is associated with cardiometabolic risk factors in East Asian population: an updated meta-analysis","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"10.1016\/j.metabol.2026.156549_bb0265","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S2213-8587(24)00195-5","article-title":"Adiposity and metabolic health in Asian populations: an epidemiological study using dual-energy x-ray absorptiometry in Singapore","volume":"12","author":"Mina","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.metabol.2026.156549_bb0270","doi-asserted-by":"crossref","DOI":"10.1111\/ijpo.70075","article-title":"BMI percentile cutoffs for overweight and obesity are set too high in terms of adiposity and metabolic markers for Asian children and adolescents","volume":"21","author":"Hong","year":"2026","journal-title":"Pediatr Obes"},{"issue":"4","key":"10.1016\/j.metabol.2026.156549_bb0275","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2021.10.025","article-title":"The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge?","volume":"76","author":"Lazarus","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2026.156549_bb0280","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.metabol.2026.156549_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0003920","article-title":"Incidence trends and specific risk factors of ischemic heart disease and stroke: an ecological analysis based on the Global Burden of Disease 2019","volume":"4","author":"Xia","year":"2024","journal-title":"PLOS Global Public Health"},{"issue":"3","key":"10.1016\/j.metabol.2026.156549_bb0290","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cmet.2023.02.003","article-title":"The global burden of metabolic disease: data from 2000 to 2019","volume":"35","author":"Chew","year":"2023","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.metabol.2026.156549_bb0295","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/CIRCULATIONAHA.115.018585","article-title":"Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.metabol.2026.156549_bb0300","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005375","article-title":"Mortality from ischemic heart disease: analysis of data from the World Health Organization and coronary artery disease risk factors from NCD Risk Factor Collaboration","volume":"12","author":"Nowbar","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"32","key":"10.1016\/j.metabol.2026.156549_bb0305","doi-asserted-by":"crossref","first-page":"19566","DOI":"10.1073\/pnas.2011228117","article-title":"Essential and sex-specific effects of mGluR5 in ventromedial hypothalamus regulating estrogen signaling and glucose balance","volume":"117","author":"Fagan","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.metabol.2026.156549_bb0310","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.tem.2023.07.003","article-title":"The impact of chromosomal sex on cardiometabolic health and disease","volume":"34","author":"Wiese","year":"2023","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2026.156549_bb0315","doi-asserted-by":"crossref","first-page":"E393","DOI":"10.1152\/ajpendo.00096.2025","article-title":"Sex-specific difference in intestinal glucose metabolism is associated with sexually dimorphic postprandial lactate shuttle and glucose homeostasis in mice","volume":"329","author":"Wang","year":"2025","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.metabol.2026.156549_bb0320","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/gutjnl-2023-330962","article-title":"Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes","volume":"73","author":"Wester","year":"2024","journal-title":"Gut"},{"issue":"12 Suppl 11","key":"10.1016\/j.metabol.2026.156549_bb0325","first-page":"10","article-title":"Use of glucagon-like peptide-1 receptor agonists in patients with MASLD in a real-world setting is associated with slower disease progression and lower all-cause mortality","volume":"20","year":"2024","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"1","key":"10.1016\/j.metabol.2026.156549_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10238-024-01553-3","article-title":"Comparative application of MAFLD and MASLD diagnostic criteria on NAFLD patients: insights from a single-center cohort","volume":"25","author":"Elsabaawy","year":"2025","journal-title":"Clin Exp Med"},{"issue":"3","key":"10.1016\/j.metabol.2026.156549_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.numecd.2024.103799","article-title":"Is MAFLD better than NAFLD in predicting the risk of major cardiovascular diseases? Evidence from a 7-year prospective cohort study","volume":"35","author":"Wang","year":"2025","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"6","key":"10.1016\/j.metabol.2026.156549_bb0340","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.metabol.2026.156549_bb0345","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.4254\/wjh.v15.i11.1210","article-title":"Global burden of cirrhosis and other chronic liver diseases due to nonalcoholic fatty liver disease, 1990-2019","volume":"15","author":"Liu","year":"2023","journal-title":"World J Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2026.156549_bb0350","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1186\/s12889-025-23318-7","article-title":"Hybrid time series and machine learning models for forecasting cardiovascular mortality in India: an age specific analysis","volume":"25","author":"Teja","year":"2025","journal-title":"BMC Public Health"},{"issue":"12","key":"10.1016\/j.metabol.2026.156549_bb0355","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1136\/gutjnl-2024-332481","article-title":"Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease","volume":"73","author":"Mao","year":"2024","journal-title":"Gut"},{"issue":"10520","key":"10.1016\/j.metabol.2026.156549_bb0360","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/S0140-6736(25)02114-2","article-title":"Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study","volume":"406","author":"Noureddin","year":"2025","journal-title":"Lancet"},{"issue":"10440","key":"10.1016\/j.metabol.2026.156549_bb0365","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","article-title":"Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021","volume":"403","year":"2024","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.metabol.2026.156549_bb0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13690-021-00537-z","article-title":"Policy-makers\u2019 views on translating burden of disease estimates in health policies: bridging the gap through data visualization","volume":"79","author":"Lundkvist","year":"2021","journal-title":"Arch Public Health"},{"issue":"5","key":"10.1016\/j.metabol.2026.156549_bb0375","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jhep.2024.01.014","article-title":"Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease","volume":"80","author":"Younossi","year":"2024","journal-title":"J Hepatol"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526000582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526000582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:02:47Z","timestamp":1779109367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049526000582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":75,"alternative-id":["S0026049526000582"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156549","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rising burden of MASLD and CKM syndrome in Asia: A decade of trends and future projections","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156549","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"156549"}}